You are probably here because someone suggested IVF and you want to know whether there is another option. Or you have already tried IVF and it did not work, and you are asking what comes next. Or you have been told your infertility is "unexplained" and that label has never sat right with you.
NaProTechnology is a diagnostic and treatment system that uses the Creighton Model cycle chart as a clinical tool to identify and correct the underlying causes of infertility. IVF is a laboratory procedure that bypasses those causes to achieve a pregnancy. This page compares them directly, with the actual evidence, so you can ask the right questions.
How NaProTechnology and IVF compare at a glance
The two approaches answer different clinical questions, so several rows below are not like-for-like comparisons. Each cited figure links to the source study.
| NaProTechnology | IVF | |
|---|---|---|
| Philosophy | Diagnose and treat the underlying condition causing infertility | Bypass the underlying condition to achieve pregnancy |
| Typical total cost | A fraction of IVF: diagnostic workup runs in the low thousands; surgery is a one-time cost | $10,000-$15,000 per cycle; $40,000-$60,000+ for a full course |
| Success metric | Adjusted cumulative live birth rate per couple over a course of treatment | Per-cycle or per-embryo-transfer live birth rate |
| Reported outcomes | 41% crude live birth (Boyle 2025, n=187); 62.1% adjusted cumulative take-home baby rate (Sanchez-Mendez 2025, n=1,310) | Approximately 33% per embryo transferred under age 35 (HFEA); declines sharply with age |
| After failed IVF | 32.1% adjusted live birth rate in couples with mean 2.1 prior failed IVF cycles (Boyle/de Groot 2018, n=403) | Declining returns with each additional cycle; underlying condition still unaddressed |
| Surgical training | Fellowship-trained in fertility-specific procedures: excision, selective HSG, tubal cannulation, adhesion prevention, ovarian wedge resection | No minimum requirement for endometriosis or tubal surgery in REI fellowship guidelines |
| Key risks | Standard medical and surgical risks; no pharmacological overstimulation | Ovarian hyperstimulation syndrome, multiple pregnancy, prematurity, elevated preeclampsia risk |
| Long-term health | Underlying condition addressed; future pregnancies benefit from the same treated biology | Underlying condition remains unaddressed after delivery |
| Insurance | Individual components coded as standard medical procedures; coverage varies by insurer and plan | Varies by state mandate; often out-of-pocket; some states require coverage |
What is the difference between NaProTechnology and IVF?
IVF is a procedure. Ovarian stimulation produces multiple eggs. Those eggs are retrieved, fertilized in a laboratory, and one or more embryos are transferred into the uterus. The goal is pregnancy. The underlying condition, whether endometriosis, hormonal dysfunction, poor sperm quality, or something else entirely, remains after delivery. IVF works around the problem. It does not fix it.
NaProTechnology is a diagnostic and treatment system. The goal is to find out why a couple is not conceiving and correct it. That means timed hormonal testing across the full menstrual cycle, not a single day-3 draw. It means investigating the luteal phase, cervical mucus quality, ovulatory function, and male factor. It means surgical evaluation when the history suggests endometriosis, tubal occlusion, or adhesive disease. And it means treating what is found: excising endometriosis, unblocking tubes through selective salpingography, optimizing progesterone support, correcting thyroid and metabolic dysfunction.
The standard infertility workup most couples receive before being referred to IVF is genuinely limited. A progesterone level drawn on cycle day one tells you almost nothing about luteal function. A standard HSG identifies gross tubal obstruction but misses partial occlusion and cannot treat what it finds. Laparoscopy for unexplained infertility is explicitly recommended against by major professional societies. The result: a couple is told their infertility is "unexplained" when in fact it is undiagnosed.
In restorative practice, an "unexplained" label is treated as an unfinished workup rather than a final diagnosis. It often means the diagnostic tools were not thorough enough to find the answer. Clinicians practicing NaProTechnology report that thorough evaluation consistently finds identifiable causes in patients previously labeled unexplained: stage IV endometriosis, bilateral tubal occlusion, luteal phase defects, thyroid dysfunction, male factor. Multiple conditions, all present, none identified. The same couple sent to IVF without any of this information.
IVF's procedural model also creates risks that the restorative model does not. Ovarian hyperstimulation, multiple gestation, and elevated rates of pregnancy complications are documented consequences of the pharmacological stimulation protocol, not rare outliers. NaProTechnology does not introduce the iatrogenic risks specific to ovarian stimulation, because it does not impose artificial stimulation. It works to restore what the body is already trying to do.
There is also a difference in what happens to the underlying disease. A woman with PCOS who conceives via IVF still has PCOS after delivery. The insulin resistance, cardiovascular risk, and metabolic complications remain. A woman treated through NaProTechnology for PCOS has her hormonal environment corrected. The fertility outcome and the long-term health outcome point in the same direction. That is the core distinction: not a debate about which technology is more advanced, but a difference in what the goal of treatment actually is.
For a full explanation of how RRM works as a field, see What is Restorative Reproductive Medicine?
How do success rates compare?
The most frequently cited statistic in fertility medicine is the IVF live birth rate per cycle. For women under 35, the HFEA (the UK's mandatory fertility reporting body) reports approximately 33% per embryo transferred. That number drops with age: to roughly 17% at ages 38-39, 11% at 40-42, and below 5% after 42. What those per-cycle numbers do not capture: most couples do not conceive on the first cycle. They attempt two, three, or more. The cumulative cost and cumulative exposure to the pharmacological protocol compound with each round. Per-cycle statistics also do not account for the couples who stop treatment after repeated failures, meaning the published rate reflects only those who persisted through the full process.
NaProTechnology measures outcomes differently. Success is reported as a cumulative live birth rate per couple over a course of treatment. This is a more informative metric. It asks: what is a couple's actual probability of going home with a baby across their entire treatment?
Three primary cohort studies and one systematic review anchor the current evidence.
Boyle et al., 2025 is the first published head-to-head comparison of RRM outcomes against IVF registry data. (Boyle et al., Journal of Restorative Reproductive Medicine, 2025) This study followed 187 couples treated at one clinic in Dublin, Ireland in 2019. The mean female age was 36.4 years. Couples had been trying to conceive for a mean of 32.2 months. Nineteen percent had previously undergone IVF. The results: 52% of couples conceived, and 41% achieved a documented live birth. When benchmarked against IVF registry data, the RRM live birth rate was comparable to a single cycle of IVF with subsequent embryo transfers. Neonatal outcomes were substantially better. Only 4.0% of singleton RRM babies were born premature. The SART-reported singleton prematurity rate for IVF is 11.8%, and for all IVF pregnancies 14.4%. There were 2 sets of twins among 187 couples. Mean time to conception for couples who achieved a live birth was 12 months. Of couples who then sought a second pregnancy, 74% succeeded.
Sanchez-Mendez et al., 2025 is the largest published NaProTechnology outcomes study to date, following 1,310 couples over five years at a specialized clinic in Madrid. (Sanchez-Mendez et al., Frontiers in Reproductive Health, 2025) This was a challenging population: 27.5% had prior ART attempts, mean female age was 35.0, and median infertility duration was 24 months. The crude take-home baby rate was 35.3%. Using Kaplan-Meier survival analysis adjusted for treatment duration, the adjusted cumulative take-home baby rate was 62.1% (95% CI 58.8-65.4) at a median NaProTechnology treatment duration of 10.9 months. Age mattered substantially. Adjusted cumulative rates by age group: 83.7% for ages 18-30, 63.2% for ages 31-35, 53.3% for ages 36-40, and 24.4% for women over 40. These figures allow for specific, honest counseling about expectations at different life stages.
Boyle and de Groot et al., 2018 studied a rescue scenario: 403 couples who had already failed IVF, with a mean of 2.1 prior IVF cycles (range 1-9), mean female age 37.2, mean infertility duration 5.8 years. (Boyle PC, de Groot T, Andralojc KM, Parnell TA. Frontiers in Medicine, 2018) This is one of the hardest populations in reproductive medicine. The adjusted RRM live birth rate was 32.1%. Women aged 35-38 achieved 37.5%. Mean birth weight was 3,374g (7lb 7oz). Ninety-two percent were born at term. There was one twin pregnancy in 403 patients. No very low birth weight babies. The estimated healthcare savings from avoided multiple-pregnancy complications: approximately $285,000.
Stanford et al., 2022, the iNEST study, was a prospective cohort that enrolled 834 couples across 10 clinics in four countries (Canada, Poland, UK, and USA) to track NaProTechnology outcomes under a standardized protocol. (Stanford JB et al., Human Reproduction Open, 2022) Reviewing the RRM cohort literature, the iNEST investigators noted adjusted cumulative live birth rates ranging from 29% to 66% over up to two years of treatment, at a mean female age around 35. The value of iNEST is that it standardized outcome tracking across diverse, non-specialty practice settings.
A 2026 systematic review in Fertility and Sterility (Ganci et al., 2026) searched specifically for randomized or controlled head-to-head trials of RRM against IVF and found none, and called for them. That is a fair description of the evidence: the studies above are observational cohorts, not randomized comparisons. It is also worth putting in context. NaProTechnology studies cannot be designed as randomized controlled trials for the same reason IVF studies never were. Randomizing couples to a treatment they have not chosen is ethically prohibited. IVF was adopted as a standard of care based on case series and uncontrolled observational data. The demand that RRM meet an evidentiary standard IVF itself never met is not a scientific objection. It is a double standard.
For the full evidence review with detailed study summaries, see RRM success rates.
What are the risks of IVF compared to NaProTechnology?
NaProTechnology works to facilitate natural conception. Its risk profile is that of a spontaneous pregnancy, not a pharmacological intervention. IVF introduces a set of iatrogenic risks that do not exist in the restorative model.
Ovarian hyperstimulation syndrome
OHSS is an iatrogenic complication specific to the ovarian stimulation protocols of IVF. It ranges from mild through critical forms, and severe cases can require hospitalization for fluid accumulation, electrolyte imbalance, and blood clots (Namavar Jahromi et al., 2018). Patients with PCOS face the highest risk. OHSS is difficult to eliminate without compromising the core goal of stimulation, which is to recruit many follicles at once. NaProTechnology, which aims to restore normal single-follicle ovulation rather than override it, is not associated with OHSS, because it does not use ovarian hyperstimulation.
Multiple pregnancy
Multiple gestation is among the most consequential safety gaps between the two approaches. In United States national surveillance data, 21.4% of ART-conceived infants in 2018 were part of a multiple birth, compared to 3.3% of births in the general population (Sunderam et al., CDC ART Surveillance, 2022). Twin and higher-order pregnancies carry significantly elevated rates of preterm labor, maternal complications, NICU admission, and long-term developmental consequences for children. NaProTechnology studies consistently report near-physiological twin rates: one twin pregnancy among 403 patients in the Boyle 2018 post-IVF-failure cohort (Boyle and de Groot et al., 2018), and 2 sets of twins among 187 couples in Boyle 2025 (Boyle et al., 2025). The shift toward single embryo transfer in IVF has reduced, but not eliminated, this risk. Even among singletons, meta-analysis finds IVF and ICSI pregnancies carry an elevated preterm-birth risk independent of multiple gestation (Pandey et al., 2012, preterm relative risk 1.54).
Pregnancy complications
IVF pregnancies carry elevated rates of preeclampsia (relative risk 1.71; Almasi-Hashiani et al., 2019) and, in singleton pregnancies, of gestational diabetes and hypertensive disorders compared to natural conceptions (Pandey et al., 2012). A study of gestational surrogates that compared the same carriers' IVF-conceived pregnancies to their own naturally conceived pregnancies found worse outcomes for the IVF singletons, including a higher rate of preterm birth (Woo et al., 2017). Because the carriers served as their own controls, that design helps separate the effect of the IVF process from maternal health. NaProTechnology pregnancies are natural conceptions in a treated body.
Neonatal outcomes
Singleton babies born after IVF have prematurity rates nearly three times those of RRM-conceived singletons. The SART-reported singleton prematurity rate is 11.8%; the Boyle 2025 RRM cohort recorded 4.0% (Boyle et al., 2025). In the Boyle 2018 post-IVF-failure cohort, no very low birth weight babies were born and 92% delivered at term (Boyle and de Groot et al., 2018). These are recorded outcomes, not theoretical risks.
Long-term child health signals
The evidence on long-term child health after IVF is incomplete but shows consistent signals worth naming. A systematic review and meta-analysis found IVF-conceived singletons have an increased relative risk of birth defects compared to natural conceptions (relative risk 1.36; Hansen et al., 2013). A meta-analysis of childhood cancer found an elevated relative risk after fertility treatment (all cancers relative risk 1.33; Hargreave et al., 2013), though the authors note the signal may partly reflect underlying subfertility rather than the procedure itself. Frozen-thawed embryo transfer, now common in modern IVF, has been associated with an increased childhood cancer risk relative to natural conception in a large Nordic cohort (adjusted hazard ratio 1.65; Sargisian et al., 2022), although overall ART-versus-spontaneous cancer risk in that study was not significant and absolute numbers were small. These are signals in an incomplete dataset, not established certainties. NaProTechnology produces natural conceptions in a treated body, with no procedural step to account for.
The ethical dimension
IVF requires the creation of embryos. Most IVF cycles create more embryos than are transferred. Couples must decide what to do with those that remain: indefinite storage, donation to research, donation to other families, or destruction. Legal disputes over embryo custody are documented in courts across multiple countries. Because NaProTechnology relies on natural conception, it does not create surplus embryos, so couples do not face this decision. That is not a religious argument. It is a clinical description of how each approach works.
How much does NaProTechnology cost compared to IVF?
A full course of IVF, including retrieval cycles, medications, genetic testing, frozen embryo transfers, and monitoring, typically costs $10,000 to $15,000 per cycle in the United States. Most couples do not succeed on the first cycle. When realistic attempt numbers are factored in, total financial exposure runs $40,000 to $60,000 or more. That estimate excludes downstream costs: hospitalization for severe OHSS, high-risk obstetric management, NICU stays for premature or low birth weight newborns, or long-term care for birth complications.
NaProTechnology costs a fraction of that. Diagnostic workup, including timed hormonal panels across multiple cycle phases, anatomical evaluation, and male factor assessment, typically runs in the low thousands of dollars. Surgical intervention for endometriosis excision, tubal cannulation, or adhesion prevention is a one-time cost that differs structurally from the per-cycle billing model of IVF. Ongoing monitoring and medication add to the total, but the overall financial exposure is substantially lower.
The downstream savings are real and quantifiable. Boyle and de Groot et al. (2018) calculated potential healthcare savings from avoided multiple pregnancies in a 403-patient cohort at approximately $285,000. That estimate covered only the single twin pregnancy that occurred. It does not capture the full population-level cost difference between a 4% and a 14.4% prematurity rate.
Insurance coverage for NaProTechnology components varies by insurer, employer benefit plan, and clinician billing approach. The individual elements of an RRM workup are standard medical procedures with established billing codes and are often covered by insurance when properly documented and indicated, though coverage varies by insurer and plan. Some insurers are more familiar with IVF reimbursement pathways and may require additional documentation. Some states have begun mandating coverage for RRM treatments; the landscape is changing. Anyone evaluating options should work with their RRM clinician's billing team to verify what is covered under their specific plan before making cost assumptions in either direction.
Who is NaProTechnology for?
NaProTechnology is a full reproductive health discipline, not a fertility protocol. It applies across the reproductive lifespan: to young women with painful periods who have not yet been diagnosed, to couples actively trying to conceive, to women with recurrent pregnancy loss, and to couples who have already failed IVF and want to understand why.
The better question is: who has the most to gain from diagnosis before treatment?
- Couples with unexplained infertility. "Unexplained" means the workup did not identify a cause. In NaProTechnology, that is a starting point, not an endpoint. The standard workup misses luteal phase defects, partial tubal occlusion, cervical factor, and early endometriosis. A thorough NaProTechnology evaluation finds answers the standard workup was not designed to find. Clinicians practicing NaProTechnology report consistently finding identifiable causes in patients previously labeled unexplained.
- Women with endometriosis. Endometriosis affects an estimated 1 in 10 women. The median time to diagnosis is 9 years. Hormonal suppression masks symptoms but does not treat the disease. NaProTechnology uses excision surgery, which removes endometriosis tissue rather than suppressing symptoms, paired with adhesion prevention and post-surgical hormonal optimization to restore the pelvic environment for natural conception.
- Women with PCOS. PCOS is the most common ovulatory disorder. NaProTechnology approaches it through targeted hormonal assessment, cycle tracking to identify ovulatory dysfunction, correction of insulin resistance, and medication protocols that work with the hormonal cycle rather than overriding it. Unlike ovarian stimulation in IVF, which carries elevated risk in PCOS patients, the NaProTechnology approach aims to restore normal single-follicle ovulation.
- Couples with recurrent pregnancy loss. Two or more losses warrant investigation. NaProTechnology evaluates progesterone insufficiency across the luteal phase, thyroid dysfunction, anatomical issues, immune factors, and male factor contributions. Progesterone support in early pregnancy, guided by cycle-timed monitoring, addresses a documented mechanism of loss.
- Couples who have already failed IVF. Boyle and de Groot et al. (2018) established that couples with a mean of 2.1 prior failed IVF cycles can achieve live birth rates comparable to another cycle of IVF through RRM. When IVF fails, the productive question is: what was the underlying condition the procedure did not address?
- Couples with male factor infertility. Male factor is the sole or primary cause in approximately 20% of infertile couples, and a contributing factor in another 30-40%. NaProTechnology evaluates the male partner beyond a basic semen analysis and includes urological referral for varicocele repair when indicated. Treatment addresses the male partner's underlying health directly rather than bypassing his contribution through sperm injection procedures.
- Couples seeking care aligned with their values. Some couples have ethical concerns about embryo creation. Others want diagnosis before bypassing. Others want a clinician who remains involved through pregnancy rather than discharging them at a positive test. NaProTechnology serves all of these situations. The approach does not require religious adherence to be effective.
On timing: NaProTechnology requires cycle monitoring and unfolds over months. The Sanchez-Mendez 2025 cohort reported a median treatment duration of 10.9 months; the iNEST study followed couples for up to 36 months. That is a real commitment, and stating it plainly is fair. The comparison is not "NaProTechnology is slower, therefore worse." The comparison is: a diagnostic and treatment process that addresses the problem, versus repeated cycles of a procedure that bypasses it.
To find an RRM clinician, visit rrmacademy.org/providers/.
Continue exploring
References
- Boyle P, Toth A, Minjeur M, Turczynski C. Restorative reproductive medicine (RRM) outcomes compared to in-vitro fertilization (IVF) for the treatment of infertility: a retrospective evaluation of a 2019 clinic cohort compared to one cycle of IVF. Journal of Restorative Reproductive Medicine. 2025;1. doi:10.63264/gejytw70. View in RRM Library
- Sanchez-Mendez JI, Lombarte M, Abengozar-Muela R, et al. Natural procreative technology (NaProTechnology) for infertility: take-home baby rate and clinical outcomes in a 5-year single-center cohort of 1,310 couples. Frontiers in Reproductive Health. 2025;7:1696679. doi:10.3389/frph.2025.1696679. PMID 41323405. View in RRM Library
- Boyle PC, de Groot T, Andralojc KM, Parnell TA. Healthy singleton pregnancies from restorative reproductive medicine (RRM) after failed IVF. Frontiers in Medicine. 2018;5:210. doi:10.3389/fmed.2018.00210. PMID 30109231. View in RRM Library
- Stanford JB, Parnell T, Kantor K, et al. International Natural Procreative Technology Evaluation and Surveillance of Treatment for Subfertility (iNEST): enrollment and methods. Human Reproduction Open. 2022;2022(3):hoac033. doi:10.1093/hropen/hoac033. PMID 35974874. View in RRM Library
- Ganci D, Steeper M, Polyakov A, Sunkara SK, Wilkinson J, Lensen S. The effectiveness and safety of restorative reproductive medicine (RRM) compared to assisted reproductive technology or medically unassisted conception: a systematic review. Fertility and Sterility. 2026. doi:10.1016/j.fertnstert.2026.03.039. PMID 41966348. View in RRM Library
- Almasi-Hashiani A, Omani-Samani R, Mohammadi M, et al. Assisted reproductive technology and the risk of preeclampsia: an updated systematic review and meta-analysis. BMC Pregnancy and Childbirth. 2019;19:149. doi:10.1186/s12884-019-2291-x. PMID 31046710. View in RRM Library
- Pandey S, Shetty A, Hamilton M, Bhattacharya S, Maheshwari A. Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis. Human Reproduction Update. 2012;18(5):485-503. doi:10.1093/humupd/dms018. PMID 22611174
- Woo I, Hindoyan R, Landay M, et al. Perinatal outcomes after natural conception versus in vitro fertilization (IVF) in gestational surrogates: a model to evaluate IVF treatment versus maternal effects. Fertility and Sterility. 2017;108(6):993-998. doi:10.1016/j.fertnstert.2017.09.014. PMID 29202976
- Hansen M, Kurinczuk JJ, Milne E, de Klerk N, Bower C. Assisted reproductive technology and birth defects: a systematic review and meta-analysis. Human Reproduction Update. 2013;19(4):330-353. doi:10.1093/humupd/dmt006. PMID 23449641
- Hargreave M, Jensen A, Toender A, Andersen KK, Kjaer SK. Fertility treatment and childhood cancer risk: a systematic meta-analysis. Fertility and Sterility. 2013;100(1):150-161. doi:10.1016/j.fertnstert.2013.03.017. PMID 23562045
- Sargisian N, Lannering B, Petzold M, et al. Cancer in children born after frozen-thawed embryo transfer: a cohort study. PLoS Medicine. 2022;19(9):e1004078. doi:10.1371/journal.pmed.1004078. PMID 36048761. View in RRM Library
- Namavar Jahromi B, Parsanezhad ME, Shomali Z, et al. Ovarian hyperstimulation syndrome: a narrative review of its pathophysiology, risk factors, prevention, classification, and management. Iranian Journal of Medical Sciences. 2018;43(3):248-260. PMID 29892142. View in RRM Library
- Sunderam S, Kissin DM, Zhang Y, et al. Assisted reproductive technology surveillance - United States, 2018. MMWR Surveillance Summaries. 2022;71(4):1-19. doi:10.15585/mmwr.ss7104a1. PMID 35176012
Frequently Asked Questions
Is NaProTechnology as effective as IVF?
In many cases, NaProTechnology produces comparable or better outcomes, though the metrics are different. IVF reports per-cycle live birth rates. NaProTechnology reports cumulative live birth rates per couple over a course of treatment. These are different denominators measuring different things.
When placed side by side using appropriate metrics: the first head-to-head comparison found a 41% crude live birth rate with RRM, comparable to a single IVF cycle with subsequent embryo transfers (Boyle et al., 2025). Sanchez-Mendez et al. (2025) followed 1,310 couples and found a 62.1% adjusted cumulative take-home baby rate (Sanchez-Mendez et al., 2025). In a post-IVF-failure population, Boyle and de Groot et al. (2018) found a 32.1% adjusted live birth rate. Beyond the numbers: IVF produces a pregnancy by bypassing the underlying problem. NaProTechnology produces a pregnancy by correcting it. Consult an RRM clinician for guidance specific to your situation.
How much does NaProTechnology cost compared to IVF?
A full course of IVF, covering multiple retrieval cycles, medications, genetic testing, frozen embryo transfers, and monitoring, typically costs $40,000 to $60,000 or more. Individual cycles are quoted at $10,000 to $15,000, but most couples need more than one. Those estimates exclude costs from complications: hospitalization, high-risk obstetric care, or NICU stays for premature newborns.
NaProTechnology costs a fraction of that. Diagnostic workup, including timed hormonal panels, anatomical evaluation, and male factor assessment, runs in the low thousands of dollars. Surgical intervention, when indicated, is a one-time cost. Many individual NaProTechnology components are billed as standard medical procedures and covered by insurance when properly documented. Coverage for the integrated approach varies by insurer and plan. Anyone evaluating costs should work with their RRM clinician's billing team to understand what is covered under their specific plan. Consult an RRM clinician for guidance specific to your situation.
Can NaProTechnology work after failed IVF?
In many cases, it can, and there is direct published evidence for this. Boyle and de Groot et al. (2018) studied 403 couples who had already failed a mean of 2.1 IVF cycles (range 1-9), with a mean female age of 37.2 years and a mean infertility duration of 5.8 years. (Boyle PC, de Groot T, Andralojc KM, Parnell TA. Frontiers in Medicine, 2018) The adjusted RRM live birth rate was 32.1%. Women aged 35-38 achieved 37.5%. The study concluded that patients who have already tried IVF can achieve comparable live birth outcomes with RRM. When IVF fails, the productive question is: what was the underlying condition the procedure did not address? RRM goes back to the diagnostic starting point, evaluates what may have been missed, and applies targeted treatment to identified causes. Consult an RRM clinician for guidance specific to your situation.
What is the success rate of NaProTechnology?
Published success rates for NaProTechnology infertility treatment vary by study population and treatment duration. The largest study to date, Sanchez-Mendez et al. (2025), followed 1,310 couples over five years at a specialized clinic in Madrid. That cohort included 27.5% with prior ART attempts and a mean female age of 35.0. The adjusted cumulative take-home baby rate was 62.1% (95% CI 58.8-65.4) at a median treatment duration of 10.9 months. (Sanchez-Mendez et al., 2025) Age-stratified adjusted rates: 83.7% (ages 18-30), 63.2% (31-35), 53.3% (36-40), 24.4% (over 40). Across the RRM cohort studies, adjusted cumulative live birth rates have ranged from 29% to 66% over up to two years of treatment (Stanford et al., 2022, iNEST). For the full evidence review, see RRM success rates. Consult an RRM clinician for guidance specific to your situation.
Is NaProTechnology covered by insurance?
This question does not have a single answer, and anyone who gives a simple yes or no is oversimplifying. The individual components of a NaProTechnology evaluation and treatment plan are standard medical procedures with established billing codes. Timed hormonal testing, diagnostic laparoscopy, surgical excision of endometriosis, progesterone supplementation, thyroid evaluation, and semen analysis all have standard procedure codes and are often covered by insurance when properly documented and indicated, though coverage varies by insurer and plan. The challenge arises at the level of the integrated NaProTechnology approach. Some insurers are more familiar with IVF reimbursement pathways and may require additional documentation. Coverage depends on the insurer, the employer's benefit plan, and the clinician's billing approach. Some states have begun mandating insurance coverage for RRM treatments. The practical path: ask an RRM clinician's billing team to walk through what is covered under your specific plan. Do not assume coverage, but do not assume exclusion either. Consult an RRM clinician for guidance specific to your situation.
Do I need to be religious to use NaProTechnology?
NaProTechnology is a medical approach. Its methods are diagnostic laparoscopy, timed hormonal testing, surgical excision, cycle tracking as a clinical tool, and targeted treatment of identified conditions. None of these require religious adherence to be effective. NaProTechnology developed within a Catholic academic and clinical tradition at the Pope Paul VI Institute and is one methodology within the broader RRM field. Some clinicians who practice it do so within a faith-motivated framework. Others do not. The published evidence base, including Boyle 2025 and Sanchez-Mendez 2025, comes from clinical settings in Ireland and Spain and is grounded in published outcome data, not religious doctrine. Many couples who pursue NaProTechnology are secular. They chose it because they want answers about why they are not conceiving, because they have concerns about IVF's risks and costs, or because IVF has already failed and they want to understand why. Consult an RRM clinician for guidance specific to your situation.
How long does NaProTechnology treatment take?
NaProTechnology is a diagnostic and treatment process that unfolds over months, not a single procedure. Initial evaluation typically takes one to three menstrual cycles to allow for timed hormonal testing across multiple cycle phases, cervical mucus assessment, and male factor evaluation. Many couples also undergo diagnostic laparoscopy during this phase to evaluate for endometriosis and tubal patency. The Boyle 2025 study found an average time to conception, for couples who achieved a live birth, of 12 months (Boyle et al., 2025). The Sanchez-Mendez 2025 cohort had a median treatment duration of 10.9 months (Sanchez-Mendez et al., 2025). The iNEST study followed couples for up to 36 months. The treatment window is reusable. Unlike IVF, where each cycle is a discrete and costly event, NaProTechnology builds a corrected biological environment in which natural conception can occur across many cycles. Of couples in the Boyle 2025 cohort who then sought a second pregnancy, 74% succeeded. Consult an RRM clinician for guidance specific to your situation.
This content is for educational and reference purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified clinician about your specific situation.